The use of patient-reported outcome measures to complement clinician-reported outcomes (CROs) may yield important information for assessing disease severity and guiding treatment of psoriasis, according to a research letter published in JAMA Dermatology. Investigators found that 41.8% of patients being treated for psoriasis in routine clinical practice had a one-level difference in disease severity for Dermatology Life Quality Index (DLQI) versus Psoriasis Area Severity Index (PASI) and 35.5% had a one-level difference versus body surface area (BSA), while a two-level difference in disease severity was seen in 9.1% of patients with the DLQI versus PASI and 11.5% versus BSA. Among patients with psoriasis not meeting the criteria for systemic therapy initiation based on either PASI scores or BSA, 72.4% also did not meet criteria using DLQI. However, 10.4% of patients not meeting criteria using PASI or BSA did meet criteria using DLQI.